cannabis hope drug firm prescription cannabis drug make uk biotech firm gw pharmaceutical set approve canada drug use treat central nervous system alleviate symptom multiple sclerosis m week ago share gw pharma lose third value uk regulator say want evidence drug benefit now canadian authority say sativex drug will consider approval approximately 50000 people canada diagnose m 85000 people suffer condition uk many patient already smoke cannabis relieve symptom now gw pharma sativex mouth spray legally available m sufferer canada within next month will first time cannabisbased drug approve anywhere world represent landmark gw pharma patient m final approval canada now little formality analyst say company expect full approval sativex early 2005 delighted receive qualify notice health canada look forward receive regulatory approval sativex canada early part 2005 say gw pharma executive chairman dr geoffrey guy uk government grant gw pharma licence grow cannabis plant medical research purpose satifex consists cannabis extract contain tetrahydrocannabinol cannabidiol cocktail also prove effective treat patient arthritis thousand plant grown secret location somewhere english countryside despite hope regulatory approval last year series delay put back sativexs launch uk late news sent share gw pharma 85p 81 1135p 